Physician profile
Barry J Mark
NPI 1073527479
$15,373.77
in general payments reported to CMS, 2019-2025
40 companies · $2,414 in 2025
The $2,414 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,366 · 2020: $1,129 · 2021: $1,432 · 2022: $2,340 · 2023: $1,748 · 2024: $1,945 · 2025: $2,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,474 · Consulting Fee: $458 · Honoraria: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,473.86 |
| Consulting Fee | $458.06 |
| Honoraria | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $4,340.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,875.96 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Genzyme Corporation | $1,684.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,262.28 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Amgen INC. | $798.05 | 2020-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $665.95 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $651.83 | 2020-2025 | Takhzyro, Eohilia, Hyqvia |
| Aimmune Therapeutics, INC. | $520.80 | 2020-2024 | |
| Biocryst US Sales Co., LLC | $444.94 | 2022-2025 | Orladeyo |
| Csl Behring | $402.00 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Amneal Pharmaceuticals LLC | $390.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $362.91 | 2019-2025 | |
| Pfizer INC. | $290.54 | 2019-2024 | |
| Genentech USA, INC. | $230.96 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $187.62 | 2025 | Neffy |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.